These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 15049745)

  • 1. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
    Gibson AE; Degenhardt LJ
    Drug Alcohol Rev; 2007 Jul; 26(4):405-10. PubMed ID: 17564876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid-dependent error processing.
    Fellows-Smith J
    J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project.
    Digiusto E; Lintzeris N; Breen C; Kimber J; Mattick RP; Bell J; Ali R; Saunders JB;
    Addict Behav; 2005 Mar; 30(3):443-56. PubMed ID: 15718062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
    Ngo HT; Tait RJ; Hulse GK
    Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Shanahan MD; Doran CM; Digiusto E; Bell J; Lintzeris N; White J; Ali R; Saunders JB; Mattick RP; Gilmour S
    Addict Behav; 2006 Mar; 31(3):371-87. PubMed ID: 15972245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable mortality profile of naltrexone implants for opiate addiction.
    Reece AS
    J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of opioid substitution therapy on alcohol metabolism.
    Clark NC; Dietze P; Lenné MG; Redman JR
    J Subst Abuse Treat; 2006 Apr; 30(3):191-6. PubMed ID: 16616162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
    Tait RJ; Ngo HT; Hulse GK
    J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.
    Stimmel B
    J Addict Dis; 2001; 20(4):1-5. PubMed ID: 11760922
    [No Abstract]   [Full Text] [Related]  

  • 13. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
    Petersen H; Skauge L; Svejsø J; Ege PP
    Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

  • 15. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
    Johnson RE; Chutuape MA; Strain EC; Walsh SL; Stitzer ML; Bigelow GE
    N Engl J Med; 2000 Nov; 343(18):1290-7. PubMed ID: 11058673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing overdose mortality associated with methadone and buprenorphine treatment.
    Bell JR; Butler B; Lawrance A; Batey R; Salmelainen P
    Drug Alcohol Depend; 2009 Sep; 104(1-2):73-7. PubMed ID: 19443138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
    Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.